专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2013149864A1 VERFAHREN ZUR AEROBEN HERSTELLUNG VON ALANIN ODER EINER UNTER VERBRAUCH VON ALANIN ENTSTEHENDEN VERBINDUNG 审中-公开
标题翻译：过程进行有氧丙氨酸的生产或在消费丙氨酸产生的连接的
公开(公告)号：WO2013149864A1
公开(公告)日：2013-10-10
申请号：PCT/EP2013/056190
申请日：2013-03-25
申请人： EVONIK DEGUSSA GMBH , HENNEMANN, Hans-Georg , SCHAFFER, Steffen , WESSEL, Mirja , PÖTTER, Markus , PFEFFER, Jan, Christoph , HAAS, Thomas , GIELEN, Jasmin , ECKL, Eva-Maria , ROEDER, Silvana , KROUTIL, Wolfgang , SKERRA, Arne
发明人： HENNEMANN, Hans-Georg , SCHAFFER, Steffen , WESSEL, Mirja , PÖTTER, Markus , PFEFFER, Jan, Christoph , HAAS, Thomas , GIELEN, Jasmin , ECKL, Eva-Maria , ROEDER, Silvana , KROUTIL, Wolfgang , SKERRA, Arne
IPC分类号： C12N1/21 , C12P13/06 , C12P13/00
CPC分类号： C12P13/06 , C12P13/005
摘要： Die Erfindung betrifft Das der Erfindung zu Grunde liegende Problem wird in einem ersten Aspekt gelöst durch ein Verfahren zur Herstellung von Alanin oder einer unter Verbrauch von Alanin entstehenden Verbindung umfassend (a) Bereitstellen einer eine rekombinante Alanin-Dehydrogenase oder eine Variante davon exprimierenden Zelle, (b) Kultivieren der Zelle unter aeroben Bedingungen in Anwesenheit einer anorganischen Stickstoffquelle in einer wässrigen Phase, und (c) Kontaktieren der Zelle mit einer organischen Phase, wobei es sich bei der Zelle um eine prokaryontische oder eine niedere eukaryontische Zelle handelt.
摘要翻译：本发明涉及本发明的根本问题是在第一方面的方法用于生产丙氨酸或丙氨酸化合物的消耗新生，包括：（a）提供一种重组丙氨酸脱氢酶或其表达细胞的变体解决，（ b）培养在无机氮源的存在下在有氧条件下的细胞在水相中，和（c）与有机相接触细胞，其中它是所述细胞是原核或低等真核细胞。

12. 发明申请

WO2013020839A1 OXIDATION UND AMINIERUNG VON SEKUNDÄREN ALKOHOLEN 审中-公开
标题翻译：氧化和仲醇的胺化
公开(公告)号：WO2013020839A1
公开(公告)日：2013-02-14
申请号：PCT/EP2012/064805
申请日：2012-07-27
申请人： EVONIK DEGUSSA GMBH , HAAS, Thomas , PÖTTER, Markus , PFEFFER, Jan Christoph , KROUTIL, Wolfgang , SKERRA, Arne , LERCHNER, Alexandra , TAUBER, Katharina Christin , SATTLER, Johann H. , SCHAFFER, Steffen
发明人： HAAS, Thomas , PÖTTER, Markus , PFEFFER, Jan Christoph , KROUTIL, Wolfgang , SKERRA, Arne , LERCHNER, Alexandra , TAUBER, Katharina Christin , SATTLER, Johann H. , SCHAFFER, Steffen
IPC分类号： C12P13/00 , C12P13/04 , C12N9/04 , C12N9/10 , C12N9/00
CPC分类号： C12P13/001 , C12N9/0006 , C12N9/1096 , C12N15/63 , C12P13/005 , C12P13/04 , C12P17/04 , C12Y101/01001 , C12Y206/01 , C12Y206/01018
摘要： Die vorliegende Erfindung betrifft ein Verfahren umfassend die Schritte a) Bereitstellen eines sekundären Alkohols, b) Oxidation des sekundären Alkohols durch Kontaktieren mit einer NAD(P) + -abhängigen Alkoholdehydrogenase und c) Kontaktieren des Oxidationsproduktes aus Schritt a) mit einer Transaminase, wobei es sich bei der NAD(P) + -abhängigen Alkoholdehydrogenase und/oder der Transaminase um ein rekombinantes oder isoliertes Enzym handelt, einen Ganzzellkatalysator zur Durchführung des Verfahrens und die Verwendung eines derartigen Ganzzellkatalysators zur Oxidation eines sekundären Alkohol.
摘要翻译：本发明涉及包含以下步骤：a）提供一种仲醇，b）通过与一个NAD（P）+接触仲醇的氧化方法 - 依赖的醇脱氢酶和c）用转氨酶，这是接触步骤a的氧化产物）在NAD（P）+ - 重组的或分离的酶是依赖醇脱氢酶和/或转氨酶，对于该方法的执行情况，并于仲醇的氧化中使用这样的全细胞催化剂的全细胞催化剂。

13. 发明申请

WO2011144756A1 BIOSYNTHETIC PROLINE/ALANINE RANDOM COIL POLYPEPTIDES AND THEIR USES 审中-公开
标题翻译：生物活性聚氨酯/芳香族线圈多糖及其用途
公开(公告)号：WO2011144756A1
公开(公告)日：2011-11-24
申请号：PCT/EP2011/058307
申请日：2011-05-20
申请人： XL-PROTEIN GMBH , TECHNISCHE UNIVERSITÄT MÜNCHEN , SKERRA, Arne , BINDER, Uli , SCHLAPSCHY, Martin
发明人： SKERRA, Arne , BINDER, Uli , SCHLAPSCHY, Martin
IPC分类号： A61K38/00 , C07K7/00
CPC分类号： C07K14/00 , A61K38/00 , A61K47/645 , A61K2039/505 , C07K7/08 , C07K14/001 , C07K14/56 , C07K14/615 , C07K16/00 , C07K2317/55 , C07K2319/31
摘要： The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, wherein said biosynthetic random coil polypeptide, said biosynthetic random coil polypeptide segment or said biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. Said at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or said conjugates are described. The uses may, inter alia, comprise medical uses, diagnostic uses or uses in the food industry as well as other industrial applications, like in the paper industry, in oil recovery, etc. In particular, a drug conjugate is provided that comprises (i) a biosynthetic random coil polypeptide or polypeptide segment comprising an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least 50 proline (Pro) and alanine (Ala) amino acid residues, and (ii) a drug selected from the group consisting of (a) a biologically active protein or a polypeptide that comprises or that is an amino acid sequence that has or mediates a biological activity and (b) a small molecule drug. Furthermore, nucleic acid molecules encoding the biosynthetic random coil polypeptide or polypeptide segment and/or the biologically active, heterologous proteins as well as vectors and cells comprising said nucleic acid molecules are disclosed. In addition, the present invention provides compositions comprising the compounds of the invention as well as specific uses of the random coil polypeptide or polypeptide segment, the biologically active proteins, the drug conjugates or the nucleic acid molecules, vectors and cells of the invention. Also methods of producing and/or obtaining the inventive biosynthetic random coil polypeptides or polypeptide segments as well as of producing and/or obtaining the inventive biologically active, heterologous proteins, and/or polypeptide constructs or conjugates, like drug conjugates are provided.
摘要翻译：本发明涉及生物合成无规卷曲多肽或生物合成无规卷曲多肽片段或生物合成缀合物，其中所述生物合成无规卷曲多肽，所述生物合成无规卷曲多肽片段或所述生物合成缀合物包含仅由脯氨酸和丙氨酸氨基酸组成的氨基酸序列酸残基，其中所述氨基酸序列由至少约50个脯氨酸（Pro）和丙氨酸（Ala）氨基酸残基组成。所述至少约50个脯氨酸（Pro）和丙氨酸（Ala）氨基酸残基可以是（a）异源多肽或异源多肽构建体的组成。还描述了使用这些生物合成无规卷曲多肽或多肽片段或所述缀合物的用途和方法。用途可以包括食品工业中的医疗用途，诊断用途或用途以及其它工业应用，如造纸工业，油回收等。特别地，提供药物缀合物，其包含（i ）生物合成无规卷曲多肽或多肽片段，其包含仅由脯氨酸和丙氨酸氨基酸残基组成的氨基酸序列，其中所述氨基酸序列由至少50个脯氨酸（Pro）和丙氨酸（Ala）氨基酸残基组成，和（ii ）选自由以下组成的组的药物：（a）生物活性蛋白质或包含或具有或介导生物活性的氨基酸序列的多肽，和（b）小分子药物。此外，公开了编码生物合成无规卷曲多肽或多肽片段和/或生物活性异源蛋白质的核酸分子以及包含所述核酸分子的载体和细胞。此外，本发明提供包含本发明化合物的组合物以及本发明的无规卷曲多肽或多肽片段，生物活性蛋白质，药物缀合物或核酸分子，载体和细胞的具体用途。还提供了生产和/或获得本发明生物合成无规卷曲多肽或多肽片段以及产生和/或获得本发明的生物活性异源蛋白质和/或多肽构建体或缀合物如药物缀合物的方法。

14. 发明申请

WO2011069992A2 MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A GIVEN TARGET 审中-公开
标题翻译：人类LIPOCALIN 2（LCN2，HNGAL）具有生物目标的亲和力
公开(公告)号：WO2011069992A2
公开(公告)日：2011-06-16
申请号：PCT/EP2010/069028
申请日：2010-12-07
申请人： PIERIS AG , SKERRA, Arne , GEBAUER, Michaela , HINZ, Dominik , RAUTH, Sabine , MATSCHINER, Gabriele
发明人： SKERRA, Arne , GEBAUER, Michaela , HINZ, Dominik , RAUTH, Sabine , MATSCHINER, Gabriele
IPC分类号： G01N33/566 , C07K1/00 , C07K14/775
CPC分类号： C07K14/47 , A61K38/00 , A61K38/1709 , A61K47/60 , C07K14/775 , C07K2319/30 , G01N33/566
摘要： The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
摘要翻译：本发明涉及用于产生突变蛋白的新文库和衍生自人脂质运载蛋白2（Lcn2，hNGAL）的新型突变蛋白以及以可检测的亲和力结合给定靶的相关蛋白。本发明还涉及编码这种突变蛋白的相应核酸分子及其产生方法。本发明还涉及一种制备这种突变蛋白的方法。例如，这种突变蛋白可用于结合和消耗天然生物分子的病理形式，例如阿尔茨海默病中的淀粉样蛋白β肽，或者靶向与肿瘤新血管生成相关的纤连蛋白结构域外结构域B.

15. 发明申请

WO2006056464A3 COMPOUND WITH AFFINITY FOR THE CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN (CTLA-4) 审中-公开
公开(公告)号：WO2006056464A3
公开(公告)日：2006-06-01
申请号：PCT/EP2005/012640
申请日：2005-11-25
申请人： PIERIS PROTEOLAB AG , MATSCHINER, Gabriele , HOHLBAUM, Andreas , SCHLEHUBER, Steffen , PÖHLCHEN, Martin , SKERRA, Arne
发明人： MATSCHINER, Gabriele , HOHLBAUM, Andreas , SCHLEHUBER, Steffen , PÖHLCHEN, Martin , SKERRA, Arne
IPC分类号： C12N15/10 , C12N15/62 , C07K14/47 , A61K38/17
摘要： The present invention relates to a compound with affinity for the cytotoxic T lymphocyte - associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid. The invention also relates to amutein derived from a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat α2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein: (a) comprises amino acid replacements at at least one of the sequence position corresponding to sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, and (b) binds human CTLA-4 with a K D of 50 nM or less.The invention also relates to a pharmaceutical composition comprising such a compound or mutein as well as to various pharmaceutical uses of such a compound or mutein, for example, for the prevention and/or treatment of cancer, an auto-immune disease or an infectious disease.

16. 发明申请

WO1995032295A1 USE OF TETRACYCLINE PROMOTER FOR THE STRICTLY REGULATED PRODUCTION OF RECOMBINANT PROTEINS IN PROKARYOTIC CELLS 审中-公开
标题翻译：在原核细胞使用本TETRACYCLINPROMOTORS严格监管生产重组蛋白
公开(公告)号：WO1995032295A1
公开(公告)日：1995-11-30
申请号：PCT/EP1995001862
申请日：1995-05-17
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , SKERRA, Arne , WARDENBERG, Christina
发明人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
IPC分类号： C12N15/63
CPC分类号： C07K16/00 , C12N15/635 , C12N15/70
摘要： A prokaryotic vector contains a controllable expression control sequence that may be repressed by the tetracycline resistance gene repressor. Also disclosed is a prokaryotic cell transformed by this vector and the use of the vector or cell in a process for producing polypeptides in prokaryotes by genetic engineering.
摘要翻译：本发明涉及一种原核表达载体，它包含的由四环素抗性基因的阻遏，在该载体的原核细胞和使用所述载体的或用于在原核生物中重组生产多肽的的方法中的细胞转化的阻抑可调控的表达控制序列，

17. 发明申请

WO2013011018A1 OXIDATION UND AMINIERUNG VON PRIMÄREN ALKOHOLEN 审中-公开
标题翻译：氧化和胺化伯醇
公开(公告)号：WO2013011018A1
公开(公告)日：2013-01-24
申请号：PCT/EP2012/063994
申请日：2012-07-17
申请人： EVONIK DEGUSSA GMBH , PÖTTER, Markus , HAAS, Thomas , PFEFFER, Jan, Christoph , SKERRA, Arne , KROUTIL, Wolfgang , LERCHNER, Alexandra , SATTLER, Johann, H. , SCHAFFER, Steffen , TAUBER, Katharina, Christin
发明人： PÖTTER, Markus , HAAS, Thomas , PFEFFER, Jan, Christoph , SKERRA, Arne , KROUTIL, Wolfgang , LERCHNER, Alexandra , SATTLER, Johann, H. , SCHAFFER, Steffen , TAUBER, Katharina, Christin
IPC分类号： C12P13/02
CPC分类号： C12P13/001 , Y02P20/582
摘要： Die vorliegende Erfindung betrifft ein Verfahren umfassend die Schritte a) Bereitstellen eines primären Alkohols der Formel HO−(CH 2 ) x −R 1 , wobei R 1 aus der Gruppe ausgewählt ist, die −OH, −SH, −NH 2 und −COOR 2 umfasst, x wenigstens 3 ist und R 2 aus der Gruppe ausgewählt ist, die H, Alkyl und Aryl umfasst, b) Oxidieren des primären Alkohols durch Kontaktieren mit einer NAD(P) + -abhängigen Alkoholdehydrogenase, und c) Kontaktieren des Oxidationsproduktes aus Schritt a) mit einer Transaminase, wobei es sich bei der NAD(P)+-Alkoholdehydrogenase und/oder der Transaminase um ein rekombinantes oder isoliertes Enzym handelt, einen Ganzzellkatalysator zur Durchführung des Verfahrens und die Verwendung eines derartigen Ganzzellkatalysators zur Oxidation eines primären Alkohols.
摘要翻译：本发明涉及包含以下步骤：a）提供式HO-（CH 2）的伯醇X-R1，其中R 1选自-OH，-SH，-NH 2组成的组中选择的方法，和-COOR 2，x是至少是3且R 2选自以下组中：H，烷基和芳基，b）通过与一个NAD（P）+接触氧化伯醇 - 依赖的醇脱氢酶，和c）将步骤a的氧化产物接触）转氨酶，其中，所述NAD（P）+ - 重组的或分离的酶是醇脱氢酶和/或转氨酶，用于该方法的实施和伯醇的氧化使用这种全细胞催化剂的全细胞催化剂。

18. 发明申请

WO2012022742A1 BINDING PROTEINS FOR HEPCIDIN 审中-公开
标题翻译： HEPCIDIN的结合蛋白
公开(公告)号：WO2012022742A1
公开(公告)日：2012-02-23
申请号：PCT/EP2011/064086
申请日：2011-08-16
申请人： PIERIS AG , TRENTMANN, Stefan , MATSCHINER, Gabriele , SKERRA, Arne
发明人： TRENTMANN, Stefan , MATSCHINER, Gabriele , SKERRA, Arne
IPC分类号： C07K14/435
CPC分类号： C07K14/47 , A61K38/00 , C07K14/435 , C07K16/26 , C07K2317/76 , C07K2317/92 , C07K2318/20
摘要： The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.
摘要翻译：本发明涉及针对Hepcidin的新型特异性结合的治疗和/或诊断蛋白质，该蛋白质优选为脂质运载蛋白的突变蛋白。本发明还涉及编码这种蛋白质的核酸分子以及用于产生和使用这些蛋白质和核酸分子的方法。因此，本发明还涉及包含这种脂质运载蛋白的药物和/或诊断组合物，包括这些蛋白质的用途。

19. 发明申请

WO2010089171A3 METHOD FOR THE AMINATION OF POLYCYCLIC COMPOUNDS USING TRANSAMINASES 审中-公开
标题翻译：多环化合物的方法胺化使用转氨酶
公开(公告)号：WO2010089171A3
公开(公告)日：2011-06-30
申请号：PCT/EP2010050331
申请日：2010-01-13
申请人： EVONIK DEGUSSA GMBH , SIEBER VOLKER , GRAMMANN KATRIN , RUEHMANN BRODER , HAAS THOMAS , PFEFFER JAN CHRISTOPH , DODERER KAI , ROLLMANN CLAUDIA , SKERRA ARNE , RAUSCH CHRISTIAN , LERCHNER ALEXANDRA
发明人： SIEBER VOLKER , GRAMMANN KATRIN , RUEHMANN BRODER , HAAS THOMAS , PFEFFER JAN CHRISTOPH , DODERER KAI , ROLLMANN CLAUDIA , SKERRA ARNE , RAUSCH CHRISTIAN , LERCHNER ALEXANDRA
IPC分类号： C12P17/18 , C07D493/04 , C12P13/00
CPC分类号： C07D493/04 , C12P13/001 , C12P17/181
摘要： The invention relates to a method for the amination of at least one keto group in a multicyclic ring system comprising at least one keto group into an amino group, using at least one enzyme E having transaminase activity.
摘要翻译：本发明描述了至少一个具有多环体系，与转氨酶活性使用的氨基的至少一种酶E的酮基中的至少一个酮基的胺化的方法。

20. 发明申请

WO2008015239A2 MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME 审中-公开
标题翻译：眼泪脂蛋白的突变及其获得方法
公开(公告)号：WO2008015239A2
公开(公告)日：2008-02-07
申请号：PCT/EP2007057971
申请日：2007-08-01
申请人： PIERIS AG , JENSEN KRISTIAN , HUELSMEYER MARTIN , SCHLEHUBER STEFFEN , HOHLBAUM ANDREAS , SKERRA ARNE , BOUDREAU ERIC , JONES RICHARD C , KIMBER IAN , DEARMAN REBECCA
发明人： JENSEN KRISTIAN , HUELSMEYER MARTIN , SCHLEHUBER STEFFEN , HOHLBAUM ANDREAS , SKERRA ARNE , BOUDREAU ERIC , JONES RICHARD C , KIMBER IAN , DEARMAN REBECCA
IPC分类号： C12N15/09
CPC分类号： A61K38/1709 , A61K38/38 , A61K47/60 , C07K14/435 , C07K14/47 , C07K14/705 , C12N5/10 , G01N33/57407 , G01N33/57492 , G01N2333/70521
摘要： The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
摘要翻译：本发明涉及源自人泪脂质运载蛋白的新型突变蛋白。本发明还涉及编码这种突变蛋白的相应核酸分子及其产生方法。本发明还涉及生产这种突变蛋白的方法。最后，本发明涉及包含这种脂质运载蛋白突变蛋白的药物组合物以及突变蛋白的各种用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式